Icovamenib & BMF-650 (oral small molecule GLP-1) are the cornerstones of the metabolic franchise Biomea preparing icovamenib for late-stage clinical development 2025 corporate update to be presented ...
The race is on for new drugs that suppress appetite, improve glucose regulation and can replace injections. But do they really work? Zoë Beaty looks at how the health landscape is rapidly changing to ...